COMMUNIQUÉS West-GlobeNewswire

PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)
12/01/2026
Trios from 200 families who have lost a child to SUDC to be sequenced on PacBio’s Revio system with SPRQ-Nx chemistry, enabling increased diagnostic yield for grieving families MENLO PARK, Calif., Jan. 12, 2026 (GLOBE [...]
PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
12/01/2026
Q4 2025 revenue growth of 14% year-over-year, driven by strong Revio and Vega shipments and record consumables revenue MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of [...]
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
12/01/2026
The CGuard ® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- [...]
Helsinn announces new Executive Leadership Team as it celebrates 50 years
12/01/2026
Lugano, Switzerland – January 12th, 2026 – Helsinn Healthcare, a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, announces a new Executive Leadership Team as the company [...]
AOP Health’s Rapiblyk™ Now Accessible via Leading US Healthcare Improvement Companies
12/01/2026
WILMINGTON, Del., Jan. 12, 2026 (GLOBE NEWSWIRE) -- AOP Health US, LLC announced today that Rapiblyk™ (landiolol) is now more widely available across the United States through Cardinal, Cencora Specialty Distribution, [...]
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
12/01/2026
Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% SANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural [...]
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
12/01/2026
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsCRP at Day 14, with [...]
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
12/01/2026
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no approved therapy SAN [...]
Dentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization
12/01/2026
CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY), the world’s largest diversified manufacturer of professional dental products and technologies [...]
VIVUS Shares Progress on Pipeline and Key Program Milestones During the 44th Annual J.P. Morgan Healthcare Conference
12/01/2026
CAMPBELL, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with [...]
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
12/01/2026
Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare Conference WARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today reported [...]
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
12/01/2026
$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic holding of Orchestra [...]
Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
12/01/2026
Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024 Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024 CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- [...]
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
12/01/2026
Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), [...]
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
12/01/2026
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA – January 12, 2026 ( GlobeNewswire ) – MDxHealth SA (NASDAQ [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
12/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 12 January 2026 at 15:00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Cabaletta Bio Announces 2026 Strategic Priorities
12/01/2026
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to [...]
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
12/01/2026
New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026 NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new [...]
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
12/01/2026
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum